Cildraw M 25 Tablet combines Cilnidipine 10mg and Metoprolol 25mg, a clinically effective antihypertensive combination designed to provide balanced blood pressure control and cardiovascular protection. Its dual-action formula helps reduce vascular resistance and cardiac workload simultaneously.
Cilnidipine, a calcium channel blocker, relaxes vascular smooth muscles, lowering peripheral resistance, while Metoprolol, a beta-blocker, slows the heart rate and reduces myocardial oxygen demand. Together, they offer comprehensive hypertension management suitable for patients requiring mild-to-moderate intervention.
This combination is widely prescribed in essential hypertension, cardiac strain, and high-risk cardiovascular patients. Its effective yet tolerable profile makes it a preferred therapy among cardiologists and general physicians.
Adding Cildraw M 25 Tablet to your cardiology and antihypertensive segment strengthens your portfolio with a reliable, high-demand combination. It opens opportunities for hospital supply, retail pharmacy distribution, institutional tenders, export markets, and third-party manufacturing, ensuring steady demand and profitability.